ArticleJournal of molecular modeling2026
Deep learning-guided high-throughput screening and molecular dynamics simulations facilitate the discovery of potential FXIIa inhibitors.
Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextPathological thrombosis is a major cause of cardiovascular and cerebrovascular diseases. Current anticoagulants increase bleeding risk by impairing physiological hemostasis. Because coagulation factor XIIa (FXIIa) drives pathological thrombosis but is dispensable for normal hemostasis, inhibiting FXIIa may offer antithrombotic efficacy with reduced bleeding risk. However, the marked flexibility of its active site hampers the discovery of small-molecule inhibitors. Here, we developed an integrated computational workflow to address this challenge and screened a library of approximately 21 million compounds. Four structurally distinct hits (DR1-DR4) were identified. Microsecond-scale molecular dynamics simulations suggested stable binding of all four compounds to FXIIa, and binding free energy calculations suggested that DR1 and DR3 exhibited more favorable binding free energies than the reference inhibitor 1303. These compounds also showed favorable predicted pharmacokinetic properties, providing structurally distinct hits for FXIIa-targeted anticoagulant discovery.
methodsThe crystal structure of the FXIIa catalytic domain (PDB ID: 6B74) was prepared in PyMOL 3.1, and missing regions were modeled with MODELLER. To capture active-site flexibility, apo-FXIIa was subjected to three independent 1-µs molecular dynamics simulations, and a representative conformation selected by clustering was used for virtual screening. A hierarchical screening workflow was carried out in DrugFlow using KarmaDock for primary screening, CarsiDock for redocking, and RTMScore for rescoring. Drug-likeness and pharmacokinetic properties were predicted with SwissADME. Selected complexes were simulated in Amber18 using ff19SB for the protein, GAFF2 for ligands, OPC water, and AM1-BCC ligand charges, and trajectories were analyzed with CPPTRAJ in AmberTools. Binding free energies were estimated with MMPBSA.py using the MM/GBSA method, with entropy contributions evaluated by normal mode analysis. Structural visualization was performed with PyMOL and Discovery Studio Visualizer 2016.
Indexed as
Identifiers
42836876What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.